Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Two-Drug attack on blood cancer tested in new trial

NCT ID NCT01446133

Summary

This study is testing whether combining the drugs lenalidomide and rituximab can help control chronic lymphocytic leukemia (CLL), a type of blood cancer. It will involve about 120 adults with CLL who are either starting treatment for the first time or have had prior therapy. The main goals are to see how well the combination works to manage the disease and to monitor its safety over multiple treatment cycles.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.